Sparrow Pharmaceuticals Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 5
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $50.8M
Latest Deal Amount
  • Investors
  • 11

Sparrow Pharmaceuticals General Information

Description

Developer of novel, proprietary corticosteroid (CS) products intended for the care for Cushing's syndrome. The company's patented drugs (NCEs) are the basis for new proprietary drugs with steroid efficacy, inhibits a key enzyme of steroid metabolism which blocks a pathway that is responsible for many steroid side effects, thereby providing patients with access to drugs for autoimmune disease, blood cancer and transplanted organ.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 920 South West 6th Avenue
  • Suite 1200
  • Portland, OR 97204
  • United States
+1 (312) 000-0000

Sparrow Pharmaceuticals Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sparrow Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series A) 19-Jan-2021 $50.8M 000.00 000.00 Completed Clinical Trials - General
7. Later Stage VC (Series A) 13-Jan-2021 00.000 00.000 Completed Clinical Trials - General
6. Later Stage VC 25-Jun-2020 00000 00.000 Completed Clinical Trials - General
5. Early Stage VC 21-Aug-2019 00000 00000 Completed Startup
4. Grant 15-Apr-2019 00000 Completed Clinical Trials - General
3. Accelerator/Incubator 01-Jan-2019 Completed Clinical Trials - General
2. Accelerator/Incubator 28-Oct-2014 Completed Startup
1. Merger/Acquisition Completed Startup
To view Sparrow Pharmaceuticals’s complete valuation and funding history, request access »

Sparrow Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Sparrow Pharmaceuticals’s complete cap table history, request access »

Sparrow Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Robert Jacks Chief Executive Officer, President & Board Member
David Katz Ph.D Founder, President and CSO
Jeffrey Drajesk Chief Operating Officer and Vice President of Program Management
To view Sparrow Pharmaceuticals’s complete executive team members history, request access »

Sparrow Pharmaceuticals Board Members (4)

Name Representing Role Since
Bruce Galton Self Board Member & Advisor 000 0000
Gayle Kirkpatrick Sparrow Pharmaceuticals Board Member & Advisor 000 0000
Klaus Veitinger Ph.D Self Board Member 000 0000
Peter Thompson Self Board Member 000 0000
To view Sparrow Pharmaceuticals’s complete board members history, request access »

Sparrow Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sparrow Pharmaceuticals Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
OrbiMed PE/Buyout Minority 000 0000 000000 0
RiverVest Venture Partners Venture Capital Minority 000 0000 000000 0
US Venture Partners Venture Capital Minority 000 0000 000000 0
Keiretsu Forum Northwest Angel Group Minority 000 0000 000000 0
Slojo Investments Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »